Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3134278 | 0.83 | APP (0.46) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL3144634 | 0.81 | APP (0.44) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14097222 | 0.79 | APP (0.42) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28157104 | 0.74 | PTGS1 (0.35) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL5923114 | 0.73 | PTGS1 (0.43) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL14814433 | 0.72 | PTGS1 (0.33) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL15203858 | 0.71 | PTGS1 (0.41) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL31553182 | 0.71 | PTGS1 (0.48) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL492291 | 0.71 | PTGS1 (0.41) | PTGS1PDE4ALMNASLC6A6CYP2C19 | |
| SCHEMBL28739943 | 0.71 | PTGS1 (0.41) | PTGS1PDE4ALMNASLC6A6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250020997-A1 | PHOTORESIST COMPOSITIONS AND METHODS OF MANUFACTURING INTEGRATED CIRCUIT DEVICES USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-20230176481-A1 | FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2023-06-08 | — | — | US | disclosed |
| US-20180044615-A1 | STABILIZED HYDROGEN PEROXIDE COMPOSITIONS AND METHOD OF MAKING SAME | METREX RES LLC (US) | 2018-02-15 | — | — | US | disclosed |
| US-9765287-B2 | Stabilized hydrogen peroxide compositions and method of making same | METREX RESEARCH CORPORATION (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017070003-A1 | USE OF PRODRUGS OF 1,3-PROPANEDISULFONIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OF SARCOIDOSIS | KIACTA SÁRL (CH) | 2017-04-27 | — | — | WO | disclosed |
| CN-106244339-A | Hydrogen peroxide composition of stabilisation and preparation method thereof | 麦瑞斯研发有限责任公司 | 2016-12-21 | — | — | CN | disclosed |
| US-20160355760-A1 | STABILIZED HYDROGEN PEROXIDE COMPOSITIONS AND METHOD OF MAKING SAME | METREX RESEARCH LLC | 2016-12-08 | — | — | US | disclosed |
| EP-3101105-A1 | STABILIZED HYDROGEN PEROXIDE COMPOSITIONS AND METHOD OF MAKING SAME | Metrex Research LLC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1836161-B1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LTD PARTNERSHIP (CA) | 2016-07-20 | — | — | EP | disclosed |
| EP-1676835-B1 | PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT | WAKO PURE CHEM IND LTD (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
| US-4692555-A | Preparation of diphenolics | ETHYL CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | PTGS1 2925/4885PDE4A 3917/4885LMNA 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.